Samsung Bioepis announced on January 30 that it has entered into a settlement and license agreement with Regeneron and Bayer, the original drug manufacturers, regarding the sale of the ophthalmology treatment 'SB15 (Eylea)' biosimilar. The agreement covers regions outside the United States and Canada for the low-concentration formulation (40 mg/mL).

Exterior view of Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis

Exterior view of Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis

View original image

Under this license agreement, Samsung Bioepis will be able to launch SB15 in the United Kingdom (January 2026), European countries (April 2026), and other countries excluding Korea (May 2026). SB15 received approval from the European Commission in 2024, and was launched in Korea under the product name 'Afilivu' in May 2024. The original drug, Eylea, is used to treat ophthalmic diseases such as wet age-related macular degeneration, and recorded global sales of 14 trillion won in 2024.


With this settlement, Samsung Bioepis has resolved the legal uncertainties that had been the biggest obstacle to product launch. Prior to this agreement, Samsung Bioepis had struggled with the original manufacturer's aggressive 'patent evergreening' strategy regarding Eylea sales. In addition to substance patents, Eylea has built a dense patent network covering formulation and administration methods, making it necessary for biosimilar developers to go through numerous legal disputes even after obtaining approval before they could actually begin sales.



Linda Choi, Executive Vice President and Head of Commercial at Samsung Bioepis, said, "This agreement will be an important milestone in improving treatment accessibility for ophthalmology patients and will enable expanded supply of this biopharmaceutical in European and global markets. We will continue our efforts to ensure that healthcare systems, professionals, and patients around the world can more easily access our biopharmaceuticals."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing